AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Crinetics Pharmaceuticals, Inc. Director's Dealing 2020

Feb 11, 2020

31156_dirs_2020-02-11_dcef7975-fa7a-4fa9-b71c-8a9f83a4bb3c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-12-31

Reporting Person: Wilson Marc (CFO and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-20	Common Stock	J	1471	$14.45	Acquired	58792	Direct

Footnotes

F1: Shares purchased under Crinetics Pharmaceuticals, Inc 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).

F2: Includes 29,090 shares of restricted stock which remain subject to continued vesting.